Unlike prior studies of AMD development that were limited to patients with diabetes, the authors wrote in their paper, their findings suggest that GLP-1 drugs "may be associated with reduced risk even in individuals with obesity but not diabetes, potentially supporting a protective benefit independent of glycemic control and mitigating diabetes as a confounding factor.
(example: 2S, never above 8.4v) Never leave a charging battery unattended
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, et al
doi:10.2337/db10-0474 114
Circulation 2000